therapy. Persistence (remaining on therapy at 12 months after therapy initiation), mean medication possession ratio (MPR) over 12 months, and adherence (adherent to statin defined as MPR ≥ 0.8) were assessed. RESULTS: Among the 281,564 patients selected, 159,833 (56.8%) started on atorvastatin, 66,526 (23.6%) on simvastatin, 27,187 (9.7%) on pravastatin, 20,921 (7.4%) on fluvastatin, and 7,097 (2.5%) on lovastatin. The mean age was 61.3+/-13.2 years and 51% were male. The persistence at 12 months, mean MPR over 12 months, and adherence rate for all statins was 52.5%, 68.7%, 52.6%, respectively. The persistence rate at 12 months for patients initiated on atorvastatin, simvastatin, fluvastatin, pravastatin, and lovastatin was 54.1%, 53.7%, 49.7%, 44.8%, 41.0%, respectively (p < 0.0001 for all comparisons except for atorvastatin vs. simavastatin). OBJECTIVES: The preferred generic measure of health benefit in economic models is health-related utility. Utility provides a single measure of health-preference and has interval properties.
A number of treatments are now available to treat obesity. The purpose of this study was to characterise the relationship between health utility and obesity as measured by body mass index (BMI). METHODS: Data were extracted from the Health Outcomes Data Repository (HODaR), which includes medical histories (almost no exclusion criteria), biochemistry, healthrelated utility (EQ5D), risk factors (including height and weight) and demographic data on a large number of individuals. The data used here (n = 18,223) were from hospital inpatients and outpatients. Univariate analysis was conducted for specific subgroups and risk factors, as well as multivariate modelling. RESULTS: The general pattern was non-linear (rotated J-shaped curve). Naturally, there was wide variability but definite underlying structure to the relationship. People had highest utility when BM I = 20 kg·m -2 . Below this, utility decreases rapidly. There was a quadratic decrease in utility from BMI = 25 kg·m -2 to BMI = 35 kg·m -2 at a rate of 0.0133 utility units per unit BMI between BMI = 29 kg·m -2 to 30 kg·m -2 , increasing to 0.0325 between BMI = 34 kg·m -2 and 35 kg·m -2 . This rate of deterioration was consistent for a range of sub-group analyses: age, sex, employment status and by broad disease categories, the general association remaining the same, only the intercept varying. CONCLUSIONS: Health-related utility is a function of obesity. These data characterise this relationship for the first time, and in a large group of subjects. The pattern of this association was consistent in all subgroups investigated, and suggests that much health benefit can be achieved by reducing obesity in the general population.
PCV44 BMI, SELF-REPORTED COMORBIDITIES, AGE, AND GENDER DO NOT EXPLAIN COUNTRY-SPECIFIC DIFFERENCES IN OBESITY-RELATED QUALITY OF LIFE
Hayes RP, Bowman L Eli Lilly & Company, Indianapolis, IN, USA OBJECTIVE: QOL is an important outcome in the evaluation of weight loss interventions (e.g., drug therapy). The objective of this study was to determine whether there are country-specific differences in the perception of the impact of weight on quality of life (QOL) or comfort with food. METHODS: The Impact of Weight on Quality of Life Scale (IWQOL) was administered to a sample of 2144 obese individuals [Mean body mass index (BMI) =31.3, 63% > = 1 self-reported comorbidity, mean age = 41 years, 58% female] in Germany (n = 542), Italy (n = 503), United Kingdom (UK) (n = 539), and United States (n = 560). The IWQOL consists of 74 items forming 8 subscales: Health, Social/Interpersonal, Sexual Life, Work, Self-Esteem, Mobility, Activities of Daily Living, and Comfort with Food. For each country, Pearson correlations were calculated between demographics and IWQOL scores. To control for demographic differences in country-specific samples, differences in IWQOL scores were tested using analysis of covariance controlling for BMI, total number of self-reported comorbidities, gender, and age. RESULTS: Correlations between demographics and IWQOL subscales across countries followed a similar pattern, but the correlation coefficients calculated for Germany between most IWQOL subscale scores and BMI or total comorbidities were significantly (p < 0.05) higher. Significant (p < 0.05) country differences were found for all IWQOL scales. Pairwise comparisons showed, for example, that, compared to the other three countries, the UK sample had significantly better Esteem and Mobility scores; Germany had significantly worse Social/Interpersonal scores; and Italy had significantly less comfort with food (all p < 0.05). CONCLUSIONS: Differences in the perceived impact of weight on QOL found in this study suggest the need for more research investigating cultural differences in the perception of obesity. Such differences may impact the interpretation of patient-reported outcome scores obtained in international evaluations of obesity interventions. .5]). The proportion of MAAEs per catheter (re-)placement was 2.3% (95% CI: 1.9%-2.6%) and the proportion of stays where a CVC was (re-)placed that had a CVC-related MAAE was 2.7% (95% CI : 2.2%-3.2%). Among patients who had length of stay up to 12 days and a CVC (re-)placement, MAAE was associated with increased in-hospital mortality (OR = 2.88, 95% CI: 1.53-5.43). Among those with CVCs (re-)placed, MAAE occurrence was unrelated to age. The most common CVC (re-)placement sites were internal jugular (40%) and subclavian veins (25%). The most common specified CVC types were PICCs (19%) and pulmonary artery catheters (16%). The most common hospital locations for (re-)placement were operating rooms (35%) and critical care units (17%). Most (72%) of the stays with CVC (re-)placement had just 1; 20% had 2 CVC (re-)placements. The most common MAAEs were misplacement (22%), thrombosis or embolism (18%), coiling or kinking (10%), and pneumothorax (8%). CONCLUSIONS: Among Medicare surgical inpatients, the rate of mechanical or allergic adverse events per catheter was approximately 2%. Incomplete documentation was a barrier to studying specific types of CVCs in relation to MAAEs and their risk factors.
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PCV46
EXPLORATION OF HIGHLY ELEVATED CREATININE KINASE RESULTS AND ASSOCIATED CHOLESTEROL THERAPY IN A LARGE COMMERCIAL HEALTH PLAN
Harley C 1 , Kempf J 2 , Nelson M 1 , Riedel A 1 1 Ingenix, Eden Prairie, MN, USA; 2 AstraZeneca LP, Wilmington, DE, USA OBJECTIVE: The use of statins has been associated with risk for myotoxicity. Myopathy, defined as creatine kinase (CK) elevation greater than 10 times the upper limit of normal (ULN), occurs in 0.1-0.5% of statin users. This study describes elevated CK levels in an HMO population on cholesterol lowering therapy. METHODS: All subjects with a valid CK result during January 1 to December 31, 2001 were studied. Pharmacy claims data were linked to the laboratory results. A highly elevated result was defined as CK at least 10 ULN. RESULTS: A search of laboratory data identified 13,624 subjects with valid CK results. Most subjects had only one result (n = 10,301, 76%). Seventy-six subjects (0.6%) had a highly elevated CK result. Forty-one percent of all subjects (n = 5530) filled prescriptions for statins only, 400 (3%) filled prescriptions for non-statin cholesterol lowering therapy only, and 1473 (11%) filled prescriptions for both types of cholesterol lowering medications. Highly elevated CK results were found among 0.3% (n = 14) of statin only subjects, 0.5% (n = 2) of non-statin therapy only subjects and 0.6% (n = 9) of subjects with both medications. Of subjects with no cholesterol therapy, 0.8% (n = 53 of 6621) had a highly elevated CK result. CONCLUSIONS: We found a low rate of highly elevated CK results among those for whom results were available. The rate of highly elevated CK was higher among those with non-statin cholesterol therapy or combination therapy compared to those with statin therapy alone. Despite the low occurrence of highly elevated results, we found that a large percentage of those tested were statin users. The low incidence of highly elevated CK among monitored statin users raises questions regarding the most effective strategy for identifying patients at risk for myotoxicity.
PCV47 THE NATIONAL ANTICOAGULATION BENCHMARK AND OUTCOMES REPORT (NABOR TM ): EVIDENCE OF A SIGNIFICANT DIFFERENCE BETWEEN GUIDELINES AND ACTUAL PRACTICE
Shillington A 1 , Tapson V 2 , Hyers T 3 , Becker R 2 , Colgan K 1 1 EPI-Q, Inc, Oakbrook Terrace, IL, USA; 2 Duke University Medical Center, Durham, NC, USA; 3 CARE Clinical Research, St. Louis, MO, USA OBJECTIVE: To assess patient characteristics, risk factors and antithrombotic treatment of atrial fibrillation (AF), venous thromboembolism (VTE), acute myocardial infarction (AMI), and prophylaxis in orthopedic surgery (OS) in patients enrolled in a national multicenter anticoagulation database. METHODS: Data was retrospectively collected from hospital inpatient records at 38 US hospitals. Patients treated from July 2000-June 2003 with an ICD-9-CM or procedure code for AF, pulmonary embolus (PE), DVT, pregnancy related PE or DVT, AMI, total knee hip or knee replacement, and hip fracture surgery were randomly selected. Patients under 18 years of age, and those admitted from or discharged to another hospital were excluded. Clinical characteristics and anticoagulation management according to guidelines were analyzed. RESULTS: A total of 3778 patients were included (945 AF, 939 VTE, 966 AMI, and OS). Mean age was 66.1 years with 53.3% male and 46.7% female. Comorbidities included hypertension (59.9%), coronary artery disease (35.5%), diabetes (21.5%), and malignancy (17.3%). Surprisingly only 54.7% of AF patients with high stroke-risk received warfarin and 20.6% received no treatment. Only 50.6% of VTE patients had INR ≥ 2.0 two consecutive days prior to discontinuing heparin. Only 60.5% of those without a therapeutic INR were discharged on bridge therapy. Length of hospitalization for bridged patients was significantly less than those discharged on chronic warfarin alone (4.0 vs. 8.1 days) (P < 0.001). Only 75.5% of AMI patients received aspirin on arrival to the hospital, although 88% were discharged on aspirin and/or warfarin. Only 85.6% of the OS population received prophylaxis with heparin or LMWH, the remaining received no anticoagulation. CONCLUSIONS: These results suggest that evidence-based antithrombotic guidelines are not being consistently followed. Further evaluation of antithrombotic practices in those sites with the highest and lowest performance is warranted. It is hoped that this database will help demonstrate gaps between guidelines and actual practice.
